A SYSTEMATIC REVIEW ON THE NEW FUROSEMIDE SUBCUTANEOUS INFUSER FOR THE TREATMENT OF HEART FAILURE
Objective to evaluate, through a systematic review, the favorable and unfavorable results of using the subcutaneous furosemide infuser in patients with heart failure (HF) Methods: An integrative review was carried out, using as criteria the search in the National Library of Medicine (PubMed) and Scientific Electronic Library Online (SciELO) databases using the descriptors (i) furosemide (ii) Heart failure, (iii) subcutaneous infuser, with the Boolean operator “AND”. Studies published from 2018 to 2023 were included. Results The FDA has approved Furoscix, a subcutaneous formulation of the loop diuretic furosemide administered through a single-use body infuser, for the treatment of congestion, its safety and efficacy for use have been demonstrated at a dose of 30 mg SC over 1 hour, therefore after 12.5mg/h in the next 4 hours and the bioavailability was 99.6% compared to intravenous furosemide with two separate doses of 40mg, according to studies the health costs associated with heart failure were significantly lower in the groups that used the furosix.
A SYSTEMATIC REVIEW ON THE NEW FUROSEMIDE SUBCUTANEOUS INFUSER FOR THE TREATMENT OF HEART FAILURE
-
DOI: 10.22533/at.ed.15933323020510
-
Palavras-chave: Furosemide, subcutaneous infuser and heart failure
-
Keywords: Furosemide, subcutaneous infuser and heart failure
-
Abstract:
Objective to evaluate, through a systematic review, the favorable and unfavorable results of using the subcutaneous furosemide infuser in patients with heart failure (HF) Methods: An integrative review was carried out, using as criteria the search in the National Library of Medicine (PubMed) and Scientific Electronic Library Online (SciELO) databases using the descriptors (i) furosemide (ii) Heart failure, (iii) subcutaneous infuser, with the Boolean operator “AND”. Studies published from 2018 to 2023 were included. Results The FDA has approved Furoscix, a subcutaneous formulation of the loop diuretic furosemide administered through a single-use body infuser, for the treatment of congestion, its safety and efficacy for use have been demonstrated at a dose of 30 mg SC over 1 hour, therefore after 12.5mg/h in the next 4 hours and the bioavailability was 99.6% compared to intravenous furosemide with two separate doses of 40mg, according to studies the health costs associated with heart failure were significantly lower in the groups that used the furosix.
- Amanda Lima Souza
- Barbara Vilas Boas
- Rafaela Volpato de Freitas
- João Henrique Luz
- Lara Beltrame Spadoto
- Julie Ane Brum Tagliani
- Jair Maximiano da Silva Júnior
- Denise Gonçalves da Silva da Paixão
- Elaine aparecida lazaroni Baita
- Diogo dos Santos Serpa
- Elaine Morais de Lima
- Isadora Luísa de Paiva Matté
